IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM.

Sparteine is a class 1a antiarrhythmic agent, a sodium channel blocker. The deficient debrisoquine hydroxylation of Sparteine is due to the absence of P-450IID1 protein in the livers of poor metabolizers.

Alismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of anginal attacks.